Dose Insider / Glossary / Foundayo

FoundayoWhat it is, how it is taken and what it did in trials

Updated November 20, 2026 路 4 min read 路 FOUNDAYO prescribing information, DailyMed, August 2026

Foundayo is the brand name of orforglipron, a once-daily tablet made by Eli Lilly and approved in the United States in 2026 for weight management.

11.1%17.2 mg, weight lost by week 72
Weight lost by week 72Adults without diabetes, % of starting weight17.2 mg11.1%9 mg8.3%5.5 mg7.4%Placebo2.1%Weight lost by week 72Adults without diabetes, % of starting weight17.2 mg11.1%9 mg8.3%5.5 mg7.4%Placebo2.1%

35.9% on 17.2 mg lost at least 15% of their starting weight.

On this page

Used with a reduced-calorie diet and more physical activity, it is approved to lower body weight and keep it off in adults with obesity, or with overweight and at least one weight-related condition. Like semaglutide it is a GLP-1 receptor agonist, but unlike the semaglutide tablets it can be taken with or without food.1

What it is

Orforglipron binds to and activates the GLP-1 receptor, the same target as semaglutide. The label says GLP-1 regulates appetite and calorie intake, that the drug decreases food intake, likely through lower appetite, and that it delays stomach emptying.1

The molecule is built very differently. Semaglutide is a modified copy of the GLP-1 hormone with a molecular weight of 4,113.58; orforglipron calcium has a molecular formula with 48 carbon atoms and a molecular weight of 902.0.1,2 That difference shows up in absorption. About 77% of a 0.8 mg dose of orforglipron reaches the blood, against 1% to 2% of an Ozempic or Wegovy tablet, and the label found no clinically relevant effect of food on it.1,3 It peaks 4 to 8 hours after a dose and has a half-life of about 29 to 49 hours, which suits once-daily dosing.1

How the dose climbs

The tablet is taken once a day, with or without food, swallowed whole. The label sets six steps, each held for at least 30 days.1

At that pace the first 17.2 mg tablet comes after at least 150 days. A missed tablet is taken as soon as possible, without doubling the next one; after 7 or more missed days in a row, the label says to restart the climb at a lower dose.1 Some medicines change the limits. Orforglipron is broken down mainly by the liver enzyme CYP3A4, so with a strong CYP3A4 inhibitor the maximum is 9 mg a day, and strong CYP3A4 inducers are to be avoided. The label tells people on birth control pills to switch to a non-oral method, or add a barrier method, for 30 days after starting and after each increase.1

What it did in trials

Two 72-week placebo-controlled trials support the approval. They used an investigational formulation, and the label reports them as the equivalent Foundayo doses of 5.5, 9 and 17.2 mg.1

Trial 1, ATTAIN-1, enrolled 3,127 adults without type 2 diabetes, who started at an average of about 102 to 104 kg. Weight fell by 7.4%, 8.3% and 11.1% on the three doses, against 2.1% on placebo. A loss of at least 15% was reached by 14.3%, 20.1% and 35.9%, against 6% on placebo.1

Trial 2, ATTAIN-2, enrolled 1,613 adults with type 2 diabetes.4 Weight fell by 5.1%, 7.0% and 9.6%, against 2.5% on placebo.1 For comparison, the Wegovy 25 mg tablet lowered weight by 13.6% at week 64 in its own trial, against 2.4% on placebo; the two drugs were not tested against each other.3

Side effects and warnings

In the pooled trials, nausea was reported by 26%, 34% and 35% on 5.5, 9 and 17.2 mg, against 10% on placebo. Constipation was reported by 20% to 27% against 9%, diarrhea by 21% to 25% against 11%, and vomiting by 13% to 24% against 4%.1 Our page on nausea on a GLP-1 covers what helps.

Foundayo carries the same boxed warning about thyroid C-cell tumors as the injectable GLP-1 medicines and must not be used by people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. It is not to be combined with another GLP-1 receptor agonist.1

Foundayo in eight lines

FactFoundayo
Active ingredientOrforglipron
MakerEli Lilly
First U.S. approval2026
FormTablet, once a day
FoodWith or without
Doses0.8 mg to start, up to 17.2 mg
Half-lifeAbout 29 to 49 hours
Approved forWeight, in adults

FOUNDAYO prescribing information, DailyMed version of August 13, 2026.1

The other GLP-1 tablet for weight is the Wegovy tablet, which must be taken on an empty stomach with a little water and a 30-minute wait; our page on how to take the Wegovy pill explains why. Our page on GLP-1 costs without insurance lists self-pay prices.

Sources

  1. FOUNDAYO (orforglipron) tablets prescribing information. Eli Lilly and Company; DailyMed, U.S. National Library of Medicine, version published August 13, 2026; sections 1, 2, 4, 5, 6.1, 7, 8.3, 11, 12 and 14. dailymed.nlm.nih.gov
  2. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; section 11. accessdata.fda.gov
  3. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 12.3 and 14. accessdata.fda.gov
  4. ClinicalTrials.gov records NCT05869903 (ATTAIN-1) and NCT05872620 (ATTAIN-2), sponsor Eli Lilly and Company; read November 20, 2026. The label reports these trials by registry number. clinicaltrials.gov

Related analyses

Log each Foundayo tablet and see your doses, weight and symptoms together.

Open Dose Insider